AstraZeneca and Daiichi Sankyo ... in lung cancer, which they are developing as part of their ongoing partnership. Results announced at the World Conference on Lung Cancer came from Enhertu ...

AstraZeneca and Daiichi Sankyo are ... to understand Enhertu’s safety profile in first-line treatment, especially on the potentially dangerous side effect of interstitial lung disease (ILD).

European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups with Enhertu ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently ... of each therapy. Enhertu’s label carries a black box warning for the risk of interstitial lung disease.

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca ... In October 2023, the EC approved Enhertu for treating advanced non-small cell lung cancer patients with a HER2 ...

After Enhertu, Datroway, and HER3-DXd, Daiichi Sankyo’s other ADCs are still early stage. Datroway's disappointing readout in second line lung cancer in 2024 has significantly lowered investor ...

AstraZeneca and Daiichi Sankyo ... first-line lung cancer. Fujifilm Diosynth Biotechnologies signed a 10-year manufacturing contract with Regeneron. 1. AstraZeneca, Daiichi say Enhertu delivers ...

The chance of patients still being alive at one year was 51.9% with AZ and Daiichi Sankyo’s drug and 28.9% in the control arm. Around 20% of gastric cancer are HER2-positive.

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...